301 related articles for article (PubMed ID: 22214808)
1. [Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia].
Ishiguro A
Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(6):476-84. PubMed ID: 22214808
[TBL] [Abstract][Full Text] [Related]
2. How we treat a hemophilia A patient with a factor VIII inhibitor.
Kempton CL; White GC
Blood; 2009 Jan; 113(1):11-7. PubMed ID: 18820129
[TBL] [Abstract][Full Text] [Related]
3. Review of immune tolerance induction in hemophilia A.
Schep SJ; Schutgens REG; Fischer K; Boes ML
Blood Rev; 2018 Jul; 32(4):326-338. PubMed ID: 29482894
[TBL] [Abstract][Full Text] [Related]
4. Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A.
Kruse-Jarres R
Hematology Am Soc Hematol Educ Program; 2011; 2011():407-12. PubMed ID: 22160066
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
6. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
7. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies.
Adair P; Su Y; Scott DW
Discov Med; 2013 May; 15(84):275-82. PubMed ID: 23725600
[TBL] [Abstract][Full Text] [Related]
8. Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.
Zerra PE; Cox C; Baldwin WH; Patel SR; Arthur CM; Lollar P; Meeks SL; Stowell SR
Blood; 2017 Dec; 130(23):2559-2568. PubMed ID: 28978569
[TBL] [Abstract][Full Text] [Related]
9. Escape or Fight: Inhibitors in Hemophilia A.
Merlin S; Follenzi A
Front Immunol; 2020; 11():476. PubMed ID: 32265927
[TBL] [Abstract][Full Text] [Related]
10. Management of factor VIII inhibitors.
Dimichele DM
Int J Hematol; 2006 Feb; 83(2):119-25. PubMed ID: 16513529
[TBL] [Abstract][Full Text] [Related]
11. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
Evans GL; Morgan RA
Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
[TBL] [Abstract][Full Text] [Related]
12. The importance of inhibitor eradication in clinically complicated hemophilia A patients.
Oldenburg J; Young G; Santagostino E; Escuriola Ettingshausen C
Expert Rev Hematol; 2018 Nov; 11(11):857-862. PubMed ID: 30286680
[TBL] [Abstract][Full Text] [Related]
13. Tolerance induction in hemophilia: innovation and accomplishments.
Sherman A; Biswas M; Herzog RW
Curr Opin Hematol; 2018 Sep; 25(5):365-372. PubMed ID: 29994897
[TBL] [Abstract][Full Text] [Related]
14. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
Samelson-Jones BJ; Arruda VR
Front Immunol; 2020; 11():618. PubMed ID: 32425925
[TBL] [Abstract][Full Text] [Related]
15. Catalytic activity of antibodies against factor VIII in patients with hemophilia A.
Lacroix-Desmazes S; Moreau A; Sooryanarayana ; Bonnemain C; Stieltjes N; Pashov A; Sultan Y; Hoebeke J; Kazatchkine MD; Kaveri SV
Nat Med; 1999 Sep; 5(9):1044-7. PubMed ID: 10470082
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives.
Ananyeva NM; Lacroix-Desmazes S; Hauser CA; Shima M; Ovanesov MV; Khrenov AV; Saenko EL
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):109-24. PubMed ID: 15090997
[TBL] [Abstract][Full Text] [Related]
17. Tolerating Factor VIII: Recent Progress.
Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
Front Immunol; 2019; 10():2991. PubMed ID: 31998296
[TBL] [Abstract][Full Text] [Related]
18. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
Franchini M; Lippi G
Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.
Zhang AH; Skupsky J; Scott DW
Clin Rev Allergy Immunol; 2009 Oct; 37(2):114-24. PubMed ID: 19199081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]